|Bid||272.70 x 243000|
|Ask||271.00 x 260500|
|Day's Range||270.20 - 272.90|
|52 Week Range||206.35 - 272.90|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||27.15|
|Earnings Date||Jan 26, 2016 - Feb 1, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||256.80|
DoubleLine CEO Jeffrey Gundlach talks about the millennial generation, the nation's debt and possible candidates for the 2020 presidential election, with Yahoo Finance's Julia La Roche.
DoubleLine Capital CEO Jeffrey Gundlach shares his thoughts on market risks, the possibility of a recession, Fed policy and the 2020 election. He speaks exclusively with Yahoo Finance's Julia La Roche, Jen Rogers, Myles Udland and Andy Serwer.
Aurora Cannabis reported earnings for its second quarter. The company says it accounted for about 20% of all consumer sales across Canada for the quarter. Yahoo Finance's Jackie DeAngelis and Julia La Roche discuss.
Is it time to say goodbye to the travel selfie? Yahoo Finance's Zack Guzman & Julia La Roche, along with Frank CEO & Founder Charlie Javice, discuss with Flytographer CEO & Founder Nicole Smith.
Yahoo Finance's Zack Guzman and Julia La Roche discuss one countries basic income experiment with Charlie Javice, Frank founder and CEO.
When it comes to e-commerce Amazon is the biggest name in the game, but should the company be worried about losing its top spot? We discuss with Jen Rogers, Brian Sozzi, Julia La Roche, and Adam Johnson
Hulu is changing how they advertise to subscribers by showing ads when users press pause. King's College Professor Brian Brenberg joins Yahoo Finance's Adam Shapiro, Dan Roberts, and Julia La Roche for a chat.
TOKYO—A new pill that can kill the flu virus in 24 hours with a single dose has become the most-prescribed influenza treatment in Japan, which is suffering through its worst flu season in two decades. The pill, called Xofluza, was discovered by Osaka-based Shionogi & Co. and it was approved last year by regulators in Japan and the U.S. In the U.S., it is marketed by Roche Holding AG’s Genentech unit. The drug quickly gained the top share in Japan, according to Shionogi’s data, in part because of its ease of use.
Trading data from OTC Markets Group shows that shares of government-sponsored entities Fannie Mae and Freddie Mac saw a dramatic increase in dollar trading volume last month. Common shares of Fannie Mae ...
Macrogenics stock rocketed by triple digits Wednesday after the firm said its breast cancer treatment outperformed Roche's competing drug, the blockbuster Herceptin, in a late-stage study.
Roche and Bristol-Myers Squibb are most exposed among large-cap pharmaceuticals firms to Medicare Plan B sales, notes Credit Suisse.
Switzerland's Roche will donate its new hemophilia A drug Hemlibra to a World Hemophilia Federation program, it said on Wednesday, joining rivals who also back the effort to help patients in developing countries who face treatment hurdles. Roche's donation will focus on patients who have developed resistance, or inhibitors, to current hemophilia A treatments as well as children, the Basel-based company said in a statement. Roche joins other companies including Sanofi's Bioverativ, Sobi, CSL Behring and Grifols that also have made contributions to the World Hemophilia Federation (WHF) Humanitarian Aid Program, which said it helped more than 16,000 patients in 60 countries in 2017.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2008 Severin Schwan was appointed CEO Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...
Swiss drugmaker Roche aims to broaden the use of its Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of its older mainstay Herceptin. Roche said on Tuesday it had applied for U.S. Food and Drug Administration approval for Kadcyla, a five-year-old drug, for post-surgical use in women with a form of early stage breast cancer who still show signs of disease after treatment with Herceptin and chemotherapy.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 30) Varian Medical Systems, Inc. (NYSE: VAR ) EXACT Sciences ...
’s fourth-quarter net profit should decline to 82 million euros from EUR147.7 million a year earlier, according to a consensus forecast provided by FactSet. Credit Suisse analysts expect the Spanish bank to report a core tier 1 ratio of 11.1% at the end of December, up from 11.0% in September. Swatch’s 2018 EBIT fell 10% short of UBS analysts’ expectations and its organic growth flatlined in 2H, UBS says.
Roche expects sales and earnings to rise in 2019 as new drugs more than offset competition from copies of its $20 billion-plus per year trio of cancer medicines Rituxan, Herceptin and Avastin, the Swiss drugmaker said on Thursday. Core operating profit last year climbed 9 percent to 20.5 billion Swiss francs ($20.65 billion), the company said. Roche shares were indicated 1.2 percent higher.
Swiss health care giant Roche reported a 7 percent rise in 2018 sales on Tuesday, highlighting strong demand for its new range of medicines.
Biogen stock slipped Wednesday after Roche and AC Immune opted to scrap two Alzheimer's treatment studies — leading investors to look for details of Biogen's own experimental drug.